The expression of LILRB3 and ITGB2 is also higher in AML, and LILRB3 acts as a marker for AML by modulating NF-κB signaling and promoting survival and immune evasion (Wu et al., 2021). The gene discussed is NFKB1; the disease is acute myeloid leukemia.